Enveda raised a $311M Series E at a $2B valuation to push its AI-discovered drug candidates deeper into clinical trials, the biotech said Tuesday. Catalio Capital Management led the round with participation from Iconiq, and the deal doubles the valuation Enveda carried 12 months ago. The company is one of a small group of AI-native drug developers with molecules now being tested in humans.
Enveda's premise is that useful medicines already exist in nature — inside plants and microbes — and that the bottleneck has always been finding, characterizing, and reformulating them fast enough to matter. The company uses machine learning to accelerate that search, treating the chemical libraries of the natural world as a training set rather than a curiosity cabinet. It's a distinct bet from the dominant AI-biotech playbook, which leans on generative models to design novel molecules from scratch.
Viswa Colluru founded Enveda in 2019 after an early stint at Recursion Pharmaceuticals, one of the first companies to industrialize machine learning for drug discovery. Recursion trained a generation of founders on the difficulty of turning computational hits into approved therapies, and Enveda is one of the more prominent second-wave companies to emerge from that lineage.
Key facts
- 01Enveda raised a $311M Series E led by Catalio Capital Management, with participation from Iconiq.
- 02The round values Enveda at $2B, double its valuation from 12 months earlier.
- 03Founder Viswa Colluru is an early employee of Recursion Pharmaceuticals and started Enveda in 2019.
- 04Enveda is running clinical trials on a treatment for severe skin conditions and a drug to maintain weight loss after stopping GLP-1s.
- 05No AI-discovered drug has yet won FDA approval, though several company pipelines are now in human trials.
The company currently has several candidates in patient trials. One targets severe skin conditions. Another is designed to help patients maintain weight loss after they discontinue GLP-1 drugs — a rapidly emerging clinical need as the first waves of Ozempic and Wegovy users come off treatment and rebound. Both programs are the kind of specific, addressable indications that investors want to see from AI-first biotechs, rather than platform pitches with no near-term readouts.
The $2B valuation places Enveda among the more richly valued private AI-biotech companies, and the doubling in 12 months runs against a broader biotech funding environment that has been cautious about late-stage rounds. Catalio and Iconiq are backing the thesis that AI-discovered candidates will start clearing regulatory milestones within the next few years, unlocking a step-change in what late-stage private investors are willing to pay.
That thesis has not yet been validated by the FDA. No drug discovered by an AI system has won FDA approval to date, and the industry is still waiting for the first Phase 3 readout that would prove the discovery approach translates into clinical efficacy. Several candidates from AI-first biotechs are in mid-stage trials, but the path from a computationally identified hit to an approved medicine still takes years and can fail at any stage.
Enveda's use of natural-product chemistry is also a hedge against one of the recurring criticisms of generative-AI drug design: that novel molecules produced in silico often carry unpredictable toxicity or manufacturability problems. Compounds derived from plants and microbes have, at minimum, a track record of being tolerated by living systems. That doesn't guarantee they'll work as drugs, but it narrows the search space in a way pure-generative approaches don't.
The skeptical view is straightforward: AI-native biotechs have raised billions in aggregate over the past five years without yet producing an approved drug, and clinical failure rates in the industry remain punishing regardless of how a candidate was discovered. Enveda's valuation implies that its pipeline will convert at rates above the industry baseline. That's the bet Catalio and Iconiq are underwriting, and it will be several years before the trials produce enough data to judge whether it's paying off.
The Series E moves Enveda into a smaller and more visible tier of AI-biotech companies where the pressure shifts from platform storytelling to clinical execution. Investors funding rounds at this scale are pricing in a credible path to a pivotal readout, and Enveda's dual-track strategy — a dermatology program alongside a post-GLP-1 weight-maintenance drug — gives it two distinct shots at the kind of result that would reprice the entire AI-drug-discovery category.
Working on something we should cover, or seeing a story we missed? Send leads, documents, or feedback to hello@aichatdaily.com. For sensitive tips, see our secure tips page for Signal and PGP options.
Spotted an error? Email hello@aichatdaily.com with the URL and the issue, or read our full corrections policy.
